Table 3.
Histological, biochemical and virological data on HBV genotypes C and B (mean ± SD)
| Parameter | HBV Genotype C | HBV Genotype B |
| Number of patients | 61 | 10 |
| Sex ratio (male/female) | 50/11 | 9/1 |
| Number of Sequential therapy | 20 (32.8%) | 4 (40%) |
| Number of Lamivudine therapy | 31 (50.8%) | 4 (40%) |
| Number of Interferon therapy | 10 (16.4%) | 2 (20%) |
| Mean Knodell score | ||
| Pretreatment | 8.1 ± 4.1 | 5.7 ± 3.2 |
| Post-treatment | 6.0 ± 3.4a | 5.4 ± 3.1 |
| Mean ALT level (nkat/L) | ||
| Pretreatment | 3390 ± 2438 | 2438 ± 2296 |
| Post-treatment | 901 ± 918 | 551 ± 233 |
| 24 wk off-treatment | 1503 ± 1336 | 1987 ± 1720 |
| Serum HBV DNA (log10) | ||
| Pretreatment | 7.7 ± 1.2 | 7.6 ± 0.8 |
| Post-treatment | 4.05 ± 1.3a | 4.9 ± 1.2a |
| 24 wk off-treatment | 5.1 ± 1.6 | 5.3 ± 1.3 |
| Intrahepatic HBV DNA (log10) | ||
| Pretreatment | 6.1 ± 0.9 | 5.6 ± 1.5 |
| Post-treatment | 4.9 ± 1.4a | 4.7 ± 1.2a |
| Intrahepatic ccc DNA (log10) | ||
| Pretreatment | 5.6 ± 1.1 | 5.8 ± 0.5 |
| Post-treatment | 3.5 ± 1.2a | 3.9 ± 1.9 |
| Sustained virological response rate at | ||
| 24 wk off-treatment | 29.4% (15/51) | 30% (3/10) |
| ALT normalization rate at | ||
| 24 wk off-treatment | 39.3% (24/51) | 30% (3/10) |
a
P < 0.05 vs post-treatment. ALT: Alanine aminotransferase; ccc DNA: Covalently closed circular DNA.